Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2016-08-10
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multicenter, Phase 3 study comparing the efficacy and
safety of eribulin with dacarbazine in subjects with advanced soft tissue sarcoma who have
disease progression within 6 months prior to study enrolment following standard therapies
which must have included an anthracycline, unless contraindicated and then at least one
additional regimen after failure of the anthracycline.